Showing results (221-230 of 259) with videos related to
Sort By:
Pageof 26
The Oncologist|April 23, 2017
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic SettingDaniele Generali, Filippo Montemurro, Roberto Bordonaro, et al.Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.Cancers|April 3, 2021
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort StudySerena Di Cosimo, Barbara Tagliaferri, Daniele Generali, et al.Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.Journal of the National Cancer Institute. Monographs|June 12, 2015
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013)Vito Amoroso, Daniele Generali, Thomas Buchholz, et al.Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.Seminars in Cancer Biology|January 21, 2015
Broad targeting of angiogenesis for cancer prevention and therapyZongwei Wang, Charlotta Dabrosin, Xin Yin, et al.Pageof 26